Today: 21 May 2026
Browse Category

Gold Prices 5 February 2026 - 26 March 2026

Gold and Silver Price Today: Gold Falls to $4,451, Silver Slides as Oil Spike Revives Rate-Hike Fears

Gold and Silver Price Today: Gold Falls to $4,451, Silver Slides as Oil Spike Revives Rate-Hike Fears

Spot gold fell 1.2% to $4,451.47 an ounce by 0811 GMT, while silver dropped 2.7% to $69.36. Brent crude rose above $104 a barrel as hopes for a ceasefire faded, fueling inflation concerns and pushing traders to expect higher interest rates. Markets now price in a 37% chance of a U.S. rate hike by December, with almost no chance of a cut. Precious metals saw broad declines across gold, silver, platinum, and palladium.
26 March 2026
·
B2Gold Stock Slides Again as Gold Rout Batters Miners and Clouds 2026 Outlook

B2Gold Stock Slides Again as Gold Rout Batters Miners and Clouds 2026 Outlook

B2Gold Corp shares dropped to $4.07 in U.S. trading Friday, extending an 8.5% fall from the previous session as gold prices slid to $4,566.26 an ounce. The company faces higher 2026 costs, guiding all-in sustaining costs up to $2,580 an ounce, well above last year’s $1,584. Toronto’s materials index and gold miners also fell sharply amid the sector-wide selloff.
20 March 2026
···
B2Gold Corp. Stock Falls Nearly 5% as Gold Slips Below $5,000 and Goose Risks Return

B2Gold Corp. Stock Falls Nearly 5% as Gold Slips Below $5,000 and Goose Risks Return

B2Gold shares fell nearly 5% Wednesday as gold dropped below $5,000 an ounce after the Federal Reserve held rates steady and warned on inflation. The miner’s 2026 cost outlook is based on gold at $5,000, but spot gold slid 2.9% to $4,860.21. B2Gold expects lower 2026 output, with most Goose mine production coming later in the year. Founder Clive Johnson will step down as CEO on June 4.
18 March 2026
······
B2Gold Corp Stock Drops Nearly 3% as Gold Prices Slide and 2026 Risks Return

B2Gold Corp Stock Drops Nearly 3% as Gold Prices Slide and 2026 Risks Return

B2Gold Corp’s U.S.-listed shares fell 2.9% to $5.10 Thursday, mirroring a 1.1% drop in spot gold and broader mining equities. The company’s 2025 revenue reached $3.06 billion, but it warned 2026 production may fall to 820,000-970,000 ounces with higher costs. A key permit for Fekola Regional remains pending after delays in 2025. Goose mine is expected to produce up to 230,000 ounces this year.
13 March 2026
···
Newmont stock price closes near $130 as gold flirts with $5,200 — what to watch next week

Newmont stock price closes near $130 as gold flirts with $5,200 — what to watch next week

Newmont Corp shares rose 1.98% to $130.00 Friday, bucking declines in the S&P 500 and Dow as spot gold climbed 0.8% to $5,230.56 an ounce. Bernstein upgraded Newmont to Outperform and raised its price target to $157, citing higher long-term gold forecasts. Newmont recently beat Q4 profit estimates and plans $1.4 billion in asset development. Managing director Mark C. Rodgers sold 5,147 shares at $125 on Feb. 25.
28 February 2026
··
Northern Star share price jumps as gold hits three-week high — what to watch next for ASX:NST

Northern Star share price jumps as gold hits three-week high — what to watch next for ASX:NST

Northern Star Resources shares rose 3.4% to A$29.30 on Monday, outperforming as gold hit a three-week high after a U.S. Supreme Court tariff ruling weakened the dollar. The S&P/ASX 200 fell 0.61% to 9,026. Northern Star’s ex-dividend date is March 4, with a quarterly update due April 22. The company reaffirmed full-year gold sales guidance and reported its Kalgoorlie mill expansion 86% complete.
23 February 2026
···
Evolution Mining share price slides for fifth day as gold whipsaws; what to watch next

Evolution Mining share price slides for fifth day as gold whipsaws; what to watch next

Evolution Mining shares fell 2.2% to A$14.59 in Sydney, marking a fifth straight session of losses and leaving the stock 10% below last week’s record. Gold rebounded 1.1% to $4,931.61 an ounce after a sharp drop, ahead of U.S. Federal Reserve minutes. Investors are watching Evolution’s March 3 ex-dividend date and April 15 quarterly results for further direction.
18 February 2026
···
Evolution Mining share price drops as gold cools — what investors watch next on ASX

Evolution Mining share price drops as gold cools — what investors watch next on ASX

Evolution Mining closed down 1.8% at A$14.91 in Sydney on Tuesday, extending a slide from last week’s record. Gold prices fell again, weighing on the sector and pushing the S&P/ASX All Ordinaries Gold Index down 1.2%. Trading volume for Evolution was around 4 million shares. Investors now await the company’s dividend timetable and next update.
17 February 2026
····
Northern Star share price slips as gold cools; Jefferies lifts target on ASX:NST

Northern Star share price slips as gold cools; Jefferies lifts target on ASX:NST

Northern Star Resources shares closed down 0.8% at A$28.23 Tuesday as gold prices slipped and the dollar strengthened. Jefferies raised its price target to A$35, maintaining a Buy rating. The S&P/ASX All Ords Gold Index fell about 1.2% midday, with sector peers also lower. Investors await U.S. Fed minutes Wednesday and Northern Star’s ex-dividend date on March 4.
17 February 2026
···
Evolution Mining share price slides after gold rout; what to watch before next week’s results

Evolution Mining share price slides after gold rout; what to watch before next week’s results

Evolution Mining shares fell 3.2% to around A$14.54 Thursday as gold prices slid 2.5% to $4,838.81 an ounce and the S&P/ASX 200 lost 0.4%. Gold stocks dropped 4.6% amid a stronger U.S. dollar and risk-off sentiment. Evolution will report half-year results on Feb. 11, with investors watching for cost and production updates.
5 February 2026
····
1 2 3 … 9

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop